Adagio Medical Holdings (ADGM)
NASDAQ:ADGM
Want to see ADGM full AI Analyst Report?
ADGM Stock Chart & Stats
$1.08
-$0.11(-9.46%)
At close: 4:00 PM EST
$1.08
-$0.11(-9.46%)
Day’s Range― - ―
52-Week Range$0.70 - $2.58
Previous Close$1.04
Volume669.05K
Average Volume (3M)152.12K
Market Cap
$16.08M
Enterprise Value$22.20M
Total Cash (Recent Filing)$12.91M
Total Debt (Recent Filing)$24.09M
Price to Earnings (P/E)―
Beta-0.28
Next Earnings
Aug 19, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding22,210,459
10 Day Avg. Volume84,483
30 Day Avg. Volume152,119
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap1.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.11
Enterprise Value/Ebitda-1.21
Forecast
1Y Price Target
$3.50Price Target Upside224.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.27
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal FULCRUM‑VT Trial ResultsRobust pivotal efficacy and safety data materially de‑risk the clinical profile. Strong trial outcomes support FDA review, clinician confidence, guideline consideration and reimbursement discussions—durable enablers of adoption and commercial traction if regulatory approval follows.
PMA Submission For VCLAS SystemA formal PMA filing is a structural regulatory milestone toward market authorization. Progressing to the PMA stage shifts the company toward potential commercial launch, partnerships with hospitals, and revenue generation in a sizeable VT ablation market, underpinning long‑term business scaling if approved.
IDE Expansion And Next‑gen VCLAS UltraIDE expansion validates development of a next‑gen device aiming to shorten procedures and improve manufacturability. If clinical and operational benefits are realized, this can lower per‑case time and costs, improve throughput, and create sustainable competitive differentiation and scalability.
Bears Say
Absent Revenue And Negative Gross ProfitThe company currently lacks meaningful commercial revenue and reports negative gross margins, indicating products or trials do not cover direct costs. This structural absence of sales means operations cannot be self‑funded and the business remains reliant on external capital until proven commercial adoption.
Persistent Negative Cash FlowSustained negative operating and free cash flow reflect ongoing cash burn and an inability to generate internal funding. Continued cash outflows require frequent financing, constrain R&D and commercialization investments, and raise dilution and refinancing risk absent near‑term revenue inflection.
Rapidly Rising Leverage And Constrained Balance SheetA sharp increase in leverage reduces financial flexibility and elevates refinancing and covenant risk. Higher debt burdens increase interest costs and may limit the company's ability to fund commercialization or absorb setbacks, likely forcing dilutive equity raises or costly debt restructuring if revenues are delayed.
Adagio Medical Holdings News
ADGM FAQ
What was Adagio Medical Holdings’s price range in the past 12 months?
Adagio Medical Holdings lowest stock price was $0.70 and its highest was $2.58 in the past 12 months.
What is Adagio Medical Holdings’s market cap?
Adagio Medical Holdings’s market cap is $16.08M.
When is Adagio Medical Holdings’s upcoming earnings report date?
Adagio Medical Holdings’s upcoming earnings report date is Aug 19, 2026 which is in 80 days.
How were Adagio Medical Holdings’s earnings last quarter?
Adagio Medical Holdings released its earnings results on May 12, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.02.
Is Adagio Medical Holdings overvalued?
According to Wall Street analysts Adagio Medical Holdings’s price is currently Undervalued.
Does Adagio Medical Holdings pay dividends?
Adagio Medical Holdings does not currently pay dividends.
What is Adagio Medical Holdings’s EPS estimate?
Adagio Medical Holdings’s EPS estimate is -0.33.
How many shares outstanding does Adagio Medical Holdings have?
Adagio Medical Holdings has 22,210,459 shares outstanding.
What happened to Adagio Medical Holdings’s price movement after its last earnings report?
Adagio Medical Holdings reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -1.915%.
Which hedge fund is a major shareholder of Adagio Medical Holdings?
Currently, no hedge funds are holding shares in ADGM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adagio Medical Holdings
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
ADGM Stock 12 Month Forecast
Average Price Target
$3.50
▲(224.07% Upside)
Technical Analysis
Ownership Overview
45.47% Insiders
0.47% Mutual Funds
41.61% Other Institutional Investors
12.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---